Research programme: live biotherapeutic vaccines - 4D Pharma/Merck Sharp and Dohme
Latest Information Update: 28 Nov 2023
At a glance
- Originator 4D Pharma PLC
- Class Bacteria; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Unspecified in United Kingdom (PO)
- 08 Oct 2019 4D Pharma enters into a collaboration with Merck Sharp & Dohme to develop live biotherapeutics for vaccines
- 08 Oct 2019 Early research in Unspecified indication in United Kingdom (PO)